Tremelimumab

A4DAB278 | Cancer | Approved
CTLA4/CD152
G2 / IgG2
AIO Studien gGmbH Amgen ARCAGY/GINECO Group AstraZeneca Azienda Ospedaliera Universitaria Senese Canadian Cancer Trials Group Charite - Universitatsmedizin Berlin Dana-Farber Cancer Institute Fondazione IRCCS Istituto Nazionale dei Tumori Grupo Espanol de Tumores Neuroendocrinos Hoosier Cancer Research Network Immunocore Institute Gustave-Roussy Kyoto Breast Cancer Research Network M. D. Anderson Cancer Center MedImmune Memorial Sloan-Kettering Cancer Center National Cancer Institute (USA) Northwestern University Pfizer Seoul National University Hospital UNICANCER University College London University of Maryland Greenbaum Cancer Center Yonsei University College of Medicine
Approved
Whole mAb
CP-675 CP675 CP 675 CP-675206 CP 675206 CP675206 IMJUDO Ticilimumab
5.5
IMGT PubChem (135304002) PubChem (160698442) PubChem (252166672) PubChem (347911239) PubChem (469605945) PubChem (471144016) PubChem (471146373) PubChem (472399327) PubChem (481155347) PubChem (483929367) PubChem (498128052) PubChem (519842798) Thera-SAbDab YAbS
Avg A4D Score
-0.6508
Score Range
-0.67 to -0.64
Structures
3
Avg. A4D Score per Structure
pH at Min / Max Aggregation Propensity

Associated Structural Profiles Level 2

Structure ID Source PDB Seq. Identity Avg. A4D Score pH (Min Agg.) pH (Max Agg.) Score CDR Score non-CDR
A4DAB278_5ggu_A_B 5ggu 100% -0.641 6.5 4.0 -0.049 -0.7223
A4DAB278_5ggv_H_L 5ggv 100% -0.6749 6.5 4.0 -0.0458 -0.7596
A4DAB278_5ggu_H_L 5ggu 100% -0.6364 6.5 4.0 -0.0231 -0.7205